The latest update is out from Genscript Biotech ( (HK:1548) ).

Genscript Biotech announced that its associate Legend Biotech reported preliminary net trade sales of approximately US$657 million for CARVYKTI for the quarter ended 30 June 2026, under a collaboration and license agreement with Janssen Biotech, Inc. The company cautioned that the sales data, supplied by Janssen, have not been independently verified and emphasized that investors should be aware of the risks and uncertainties affecting Legend’s product development, regulatory outlook and overall performance.

The strong quarterly sales of CARVYKTI highlight the commercial momentum of Legend’s flagship therapy, reinforcing Genscript’s indirect exposure to the fast-growing cell therapy market. However, the detailed risk warnings and forward-looking caveats underline that future results could diverge materially from current trends, urging shareholders and potential investors to exercise caution when dealing in Genscript’s securities.

The most recent analyst rating on (HK:1548) stock is a Buy
with a HK$15.50 price target.
To see the full list of analyst forecasts on Genscript Biotech stock,
see the HK:1548 Stock Forecast page.